Veracyte CEO Sells $65,800 in Stock (VCYT)
Veracyte (NASDAQ:VCYT) CEO Bonnie H. Anderson unloaded 4,000 shares of the company’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $16.45, for a total value of $65,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Veracyte (NASDAQ:VCYT) traded up 3.38% during mid-day trading on Monday, hitting $16.82. The stock had a trading volume of 211,405 shares. Veracyte has a one year low of $10.88 and a one year high of $19.00. The stock’s 50-day moving average is $14.2 and its 200-day moving average is $14.93. The company’s market cap is $356.1 million.
Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter in the prior year, the company posted ($9.04) earnings per share. The company’s quarterly revenue was up 70.5% on a year-over-year basis. On average, analysts predict that Veracyte will post $-1.31 earnings per share for the current fiscal year.
Separately, analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday. They set an “overweight” rating and a $21.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $20.50.
Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.